The high cost of prescription drugs has featured prominently in the 2020 presidential campaign, reflecting the challenge millions of Americans face in affording their medications. Of greatest concern have been routine price increases of existing brand-name drugs and rapidly escalating launch prices of novel brand-name drugs. For example, of 36 top-selling brand-name drugs available in 2012, 16 (44%) more than doubled in cost by 2019, while the average annual cost of a new brand-name cancer drug now exceeds $150,000.

Many of these products would not have made it to market without taxpayer-funded support. The US National Institutes of Health (NIH) alone accounts for more than half of the research and development (R&D) spend reported by major pharmaceutical companies each year. This funding was linked at some level to the development of all 210 novel brand-name drugs approved between 2010 and 2016. Other public entities, such as the Department of Defense and state organizations like the Cancer Prevention and Research Institute of Texas, also offer important support. Traditionally, funding from such institutions has covered basic and early-stage translational science, but a quarter of novel small-molecule brand-name drugs approved over the past decade were based in part on key late-stage publicly-supported contributions.

To better account for these contributions, some policymakers have proposed instituting fair pricing terms on applicable drugs. In August 2019, for example, Sen. Chris Van Hollen (D-MD) and Sen. Rick Scott (R-FL), introduced the We Protect American Investment in Drugs Act (We PAID Act), which would establish a Drug Affordability and Access Committee to determine reasonable prices for drugs with patents disclosing federal funding.

Although such legislation is promising, a publicly-supported organization could be a useful supplement to help advance taxpayer-supported basic and translational science findings through to regulatory approval. This is particularly important because major pharmaceutical companies — which currently take the lead on late-stage development and regulatory approval of nearly all promising new drugs — spend less than a fifth of their revenue on R&D, much less than what they do on marketing and administration. Additionally, many companies “routinely distribute more than 100 percent of profits to shareholders, generating the extra cash by reducing reserves, selling off assets, taking debt, or laying off employees.”

Pressing health needs, meanwhile, remain unmet. A focus on short-term profits has shifted drug development away from certain areas of unmet medical need or public health importance, such as cardiovascular disease. In 2019, for example, Amgen joined several other pharmaceutical companies in cutting their R&D portfolios for central nervous system drugs. This January, the World Health Organization (WHO)
sounded an alarm regarding the insufficiency of the pharmaceutical pipeline to tackle antimicrobial resistance. Of 50 antibiotics in clinical testing, only 2 were for multi-drug resistant gram-negative bacteria — the biggest infectious disease threat.

A national public pharmaceutical R&D institute for full-cycle drug development could help fill some of these gaps. This institute could be based at NIH, benefiting from close collaboration with existing institutes and their increasing involvement in early-phase clinical trials, and would focus on developing drugs of societal need, starting with discrete areas of market failure, such as antibiotics. To ensure that the institute delivers on its promise, its founding statutes could include a commitment to contributing to safe, adequate, and accessible supply of essential medicines in the US; to maximum transparency; and to management in the public interest.

A national public pharmaceutical R&D institute for full-cycle drug development could help fill some of these gaps. This institute could be based at NIH, benefiting from close collaboration with existing institutes and their increasing involvement in early-phase clinical trials, and would focus on developing drugs of societal need, starting with discrete areas of market failure, such as antibiotics. To ensure that the institute delivers on its promise, its founding statutes could include a commitment to contributing to safe, adequate, and accessible supply of essential medicines in the US; to maximum transparency; and to management in the public interest.

For greater learning from the failures or unexpected outcomes that inevitably occur as part of the R&D process. Importantly, establishment of national public pharmaceutical initiative would not be without challenges. It would require a large up-front investment by the federal government. Yet this expenditure would be offset by long-term savings from reduced drug prices and avoided health care costs. Generic prices for just one commonly used medication could reduce government expenditures by hundreds of millions of dollars. For example, the US Department of Health and Human services estimated that in 2016 alone, Medicare Part D could have saved $577 million through full generic substitution of prescriptions for the heartburn drug esomeprazole (Nexium).

The institute would also face a steep learning curve. However, there are good reasons to believe this challenge could be met. The US public sector has a long tradition of path-breaking innovation. For example, the Defense Advanced Research Projects Agency within the Department of Defense was instrumental in overseeing R&D that resulted in technological breakthroughs such as the Internet, Global Positioning System (GPS), and microchips. Close collaboration and joint funding from the Central Intelligence Agency, the Department of Energy, and the National Science Foundation spurred advances like lithium-ion batteries, while NASA put men on the moon and helped build the International Space Station. This track record hints at what might be possible if public funds were invested in pharmaceutical R&D via a publicly controlled institute with a clear mission to deliver high-quality medications that improve or extend lives of patients across disease groups.

Note
A prior version of this Commentary was posted online at The Next System Project (https://thenextsystem.org/learn/stories/national-pharmaceutical-research-and-development-institute).

Dr. Sarpatwari and Dr. Kesselheim receive support from Arnold Ventures, the Harvard-MIT Center for Regulatory Science, and the Open Society Foundations. Their work is also funded in part by a Novo Nordisk Foundation grant for a scientifically independent Collaborative Research Programme (grant NNF17SA0027784). Dr. Brown reports grants from Open Society Foundations during the conduct of the study.

References
2. A.S. Kesselheim, J. Avorn, and A. Sarpatwari, “The High Cost of Prescription Drugs in the United States: Ori-
gins and Prospects for Reform,” JAMA
316, no. 8 (2016): 858-871.
3. N.E. Wineinger, Y. Zhang, and E.J.
Topol, “Trends in Prices of Popular
Brand-Name Prescription Drugs in the
United States,” JAMA Network Open 2,
no. 5 (2019): e194791.
4. Global oncology trends 2019, IQVIA
Institute for Human Data Science,
available at <https://www.iqvia.com/
insights/the-iqvia-institute/reports/
global-oncology-trends-2019> (last
visited February 27, 2020).
5. Pharmaceutical company drug sales
as compared to R&D outlays, Knowledge
Edge International, available at <http://drugdatabase.info/pharma-
company-drug-sales-as-compared-to-rd-outlays/> (last visited
February 27, 2020).
6. C.E. Galkina, J.M. Beierlein, N.S. Kha-
uja, L.M. McNamee, and F.D. Ledley,
“Contribution of NIH Funding to New
Drug Approvals 2010-2016,” Proceed-
ings of the National Academy of Sci-
ences of the USA 115, no. 10 (2018):
2329-2334.
7. J.C. Larsen and G.L. Disbrow, “Pro-
ject BioShield and the Biomedical
Advanced Research Development
Authority: A Ten Year Progress Report
On Meeting U.S. Preparedness Object-
tives for Threat Agents,” Clinical In-
fec-tious Diseases 64, no. 10 (2017):1430-
1434; J. Kaiser, “Texas Voters Approve
Second Life for State Cancer Funding
texas-voters-approve-second-life-state-
cancer-funding-agency> (last visited
February 27, 2020).
8. R. Nayak, J. Avorn, and A.S. Kessel-
heim, “Public Sector Financial Support
for Late Stage Discovery of New Drugs
in the United States: Cohort Study,”
9. A. Sarpatwari, A.K. LaPidus, and A.S.
Kesselheim, “Revisiting the National
Institutes of Health Fair Pricing Con-
dition: Promoting Drugs Developed
with Government Support,” Annals of
Internal Medicine (2020) (E-pub ahead
of print).
10. A.S. Kesselheim, J. Avorn, and A. Sar-
patwari, “The High Cost of Prescrip-
tion Drugs in the United States: Ori-
gins and Prospects for Reform,” JAMA
316, no. 8 (2016): 858-871.
11. A. Swanson, “Big Pharmaceutical
Companies are Spending Far More on
Marketing than Research,” Washing-
washingtonpost.com/news/work/wp/2015/02/11/big-pharmaceutical-
companies-are-spending-far-more-on-
marketing-than-research> (last
visited February 27, 2020).
12. W. Lazonick, M. Hopkins, K. Jacob-
son, M.E. Sakinct, and O. Tulum,
“US Pharma’s Financialized Business
Model,” Institute for New Economic
ineteconomics.org/uploads/papers/
Final-WP_60-Lazonick-et-al.-US-
(last visited February 27, 2020).
13. A. Kaltenboeck, M. Calsyn, G.W.J.
Frederix, et al., “Grounding Value-
Based Drug Pricing in Population
Health,” Clinical Pharmacology &
Therapeutics (2020) (E-pub ahead of
print).
14. A. Dunn, “Amgen Exists Neurosci-
ence R&D as Pharma Pulls Back from
com/news/amgen-exits-neurosci-
ence-rd-as-pharma-pulls-back-from-
field/> (last visited March 13,
2020).
15. World Health Organization, “Lack
of New Antibiotics Threatens Global
Efforts to Contain Drug-Resistant
Infections,” available at <https://
www.who.int/news-room/detail/17-
01-2020-17-01-2020-lack-of-new-anti-
biotics-threatens-global-efforts-to-con-
tain-drug-resistant-infections> (last
visited February 27, 2020).
16. World Health Organization, 2019
Antibacterial Agents in Clinical
Development: An Analysis of the
Antibacterial Clinical Development
who.int/iris/bitstream/handle/10665/330420/9789240000193-
eng.pdf> (last visited February 27,
2020).
17. D. Baker, “The Future of the Phar-
maceutical Industry: Beyond Govern-
ment-Granted Monopolies,” CEPR,
available at <http://cepr.net/images/
stories/reports/pharma-indus-
try-2019-03.pdf> (last visited February
27, 2020).
18. “Savings Available under Full Gener-
ic Substitution of Multiple Source Brand
Drugs in Medicare Part D,” U.S.
Department of Health and Human
hhs.gov/system/files/pdf/259326/
DP-Multisource-Brands-in-Part-D.
pdf?utm_source=newletter&utm_
medium=email&utmcampaign=news-
letter_axiosvitals&stream=top> (last
visited February 27, 2020).
19. M. Mazzucato, The Entrepreneurial
State: Debunking Public vs. Private
Sector Myths (New York, NY: Public
Affairs; 2015).